Sermorelin acetate research and evidence overview

Sermorelin's evidence is real but narrow and old. It is a 29-amino-acid fragment of growth hormone-releasing hormone that demonstrably triggers pituitary GH release, which is why it was approved as a diagnostic and paediatric growth agent before being pulled from the market for commercial rather than safety reasons. What it does not have is a modern trial programme in healthy adults: the human data behind "anti-aging" use amount to a handful of small studies from the 1990s with mixed, sex-dependent results, and the most-cited modern reference on the topic is an editorial, not a trial.

Sermorelin was marketed in the United States as Geref for diagnostic assessment of pituitary GH secretion and for growth failure in children with GH deficiency. It was subsequently withdrawn by its manufacturer. The reason usually given in the literature is competitive, not regulatory: recombinant human GH had captured the indication. A 2006 editorial in Clinical Interventions in Aging by Richard Walker, Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?, states plainly that sermorelin could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer.

That distinction matters for how the compound is sold today. "No longer FDA-approved because it was discontinued" is a different situation from "never studied" — and also different from "approved and available," which it is not. Product supplied today comes from compounding or research channels outside the original approved supply chain.

The Walker editorial sets out the mechanistic argument that underpins most clinical interest: sermorelin binds pituitary GHRH receptors to stimulate the patient's own GH production rather than replacing the hormone directly. The claimed advantages follow from that — pulsatile rather than "square wave" hormone exposure, preservation of the GH neuroendocrine axis, and negative feedback through somatostatin that makes gross overdose difficult.

It is worth reading this source for what it is. It is an editorial containing no original trial data, published by an author writing in favour of the approach. The mechanism is uncontroversial; the therapeutic conclusion drawn from it is an argument, not a result.

The most concrete human data in older adults come from Khorram, Laughlin, and Yen (Journal of Clinical Endocrinology and Metabolism, 1997), a single-blind, randomized, placebo-controlled study of a GHRH(1-29) analogue in 10 women and 9 men aged 55 to 71. Participants self-injected saline nightly for 4 weeks, then the GHRH analogue at 10 mcg/kg for 16 weeks (PubMed 9141536).

Nocturnal GH rose significantly in both sexes, with IGF-1 and IGFBP-3 up within two weeks. Beyond that the results diverged sharply by sex: skin thickness increased in both, but lean body mass, insulin sensitivity, general well-being, and libido improved in men only, with no change in body weight, blood pressure, bone mineral density, or sleep quality in either group. The only adverse effect was transient hyperlipidaemia. Nineteen participants over four months cannot establish efficacy or safety; the authors themselves called for further work to explain the sex difference.

• A rise in IGF-1 is the expected pharmacodynamic response, not proof of a clinical benefit — it is the input, not the outcome.
• Trials in diagnosed GH deficiency do not transfer to adults with age-related decline in GH pulse amplitude.
• Most human sermorelin data predate modern body-composition and cardiovascular endpoints, and none run long enough to address them.
• Clinic marketing frequently cites the mechanistic advantages from editorials while omitting that the drug was withdrawn and that the supporting trials are small.